FESOTERODINE FUMARATE tablet, extended release

Fesoterodine Fumarate by

Drug Labeling and Warnings

Fesoterodine Fumarate by is a Prescription medication manufactured, distributed, or labeled by Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Adult Overactive Bladder

    Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.

    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.


  • 2 DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosage for Adult Patients with OAB

    The recommended starting dosage of fesoterodine fumarate extended-release tablet in adults is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of fesoterodine fumarate extended-release tablet 8 mg once daily. For administration instructions, see Dosage and Administration (2.6).

     

    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.


    2.3 Recommended Dosage in Adult Patients with Renal Impairment

    The recommended dosage of fesoterodine fumarate extended-release tablet in adult patients with renal impairment is described in Table 1 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6). 

    Table 1: Fesoterodine Fumarate Extended-Release Tablet Recommended Dose in Adult Patients with Renal Impairment (Administered Orally Once Daily)

                       

     Estimated Creatinine Clearance1 
         		 Recommended Dose
     
     CLcr 30 to 89 mL/min
         		 8 mg
     
     CLcr 15 to 29 mL/min
         		 4 mg
     
     CLcr <15 mL/min
         		 4 mg
     

    1 Calculate CLcr using the Cockcroft-Gault formula


      Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

    2.5 Fesoterodine Fumarate Extended-Release Tablets Dosage Modifications Due to Strong CYP3A4 Inhibitors

    Adult Patients with OAB

    The maximum recommended dosage is fesoterodine fumarate extended-release tablet 4 mg orally once daily in adult patients taking strong CYP3A4 inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).


      Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.


    2.6 Administration Instructions

    Swallow fesoterodine fumarate extended-release tablet whole with liquid. Do not chew, divide, or crush. Take with or without food [see Clinical Pharmacology (12.3)].

  • 3 DOSAGE FORMS AND STRENGTHS

    Fesoterodine fumarate extended-release tablets 4 mg are dark blue, oval, biconvex, film-coated tablets debossed with L376 on one side and plain on other side.

    Fesoterodine fumarate extended-release tablets 8 mg are light blue, oval, biconvex, film-coated tablets debossed with L377 on one side and plain on other side.

  • 4 CONTRAINDICATIONS

    Fesoterodine fumarate extended-release tablet is contraindicated in patients with any of the following:
    known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules [see Clinical Pharmacology (12.1)]. Reactions have included angioedema [see Warnings and Precautions (5.1)].
    urinary retention [see Warnings and Precautions (5.2)]
    gastric retention [see Warnings and Precautions (5.3)]
    uncontrolled narrow-angle glaucoma [see Warnings and Precautions (5.4)]


  • 5 WARNINGS AND PRECAUTIONS

    5.1 Angioedema

    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine. In some cases angioedema occurred after the first dose; however, cases have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life-threatening.

    Fesoterodine fumarate is contraindicated in patients with a known or suspected hypersensitivity to fesoterodine fumarate or any of its ingredients [see Contraindications (4)]. If involvement of the tongue, hypopharynx, or larynx occurs, fesoterodine fumarate should be promptly discontinued and appropriate therapy and/or measures to ensure a patent airway should be promptly provided.


    5.2 Urinary Retention in Adult Patients with Bladder Outlet Obstruction

    The use of fesoterodine fumarate, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. The use of fesoterodine fumarate is not recommended in patients with clinically significant bladder outlet obstruction, and is contraindicated in patients with urinary retention [see Contraindications (4) and Adverse Reactions (6.1)].

    5.3 Decreased Gastrointestinal Motility

    Fesoterodine fumarate is associated with decreased gastric motility. Fesoterodine fumarate is contraindicated in patients with gastric retention [see Contraindications (4)]. The use of fesoterodine fumarate is not recommended in patients with decreased gastrointestinal motility, such as those with severe constipation.

    5.4 Worsening of Narrow-Angle Glaucoma

    Fesoterodine fumarate can worsen controlled narrow-angle glaucoma. Fesoterodine fumarate is contraindicated in patients with uncontrolled narrow-angle glaucoma [see Contraindications (4)]. Fesoterodine fumarate should be used with caution in patients being treated for narrow-angle glaucoma.

    5.5 Central Nervous Systems Effects

    Fesoterodine fumarate is associated with anticholinergic central nervous system (CNS) adverse reactions [see Adverse Reactions (6.1)]. A variety of CNS anticholinergic effects have been reported, including headache, dizziness, and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how fesoterodine fumarate affects them. If a patient experiences anticholinergic CNS effects, fesoterodine fumarate dose reduction or discontinuation should be considered.

    5.6 Worsening of Myasthenia Gravis Symptoms

    Fesoterodine fumarate should be used with caution in patients with myasthenia gravis due to the risk of worsening of symptoms of the disease.


  • 6 ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in labeling:
    Angioedema [see Warnings and Precautions (5.1)]
    Urinary Retention [see Warnings and Precautions (5.2)]
    Decreased Gastointestinal Motility [see Warnings and Precautions (5.3)]


    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Adult Overactive Bladder (OAB)
    The safety of fesoterodine fumarate was evaluated in Phase 2 and 3 controlled trials in a total of 2,859 patients with overactive bladder, of which 2,288 were treated with fesoterodine fumarate. Of this total, 782 received fesoterodine fumarate 4 mg/day, and 785 received fesoterodine fumarate 8 mg/day with treatment periods of 8-or 12-weeks. Approximately 80% of these patients had greater than 10-weeks of exposure to fesoterodine fumarate in these trials.

    A total of 1,964 patients participated in two 12-week, Phase 3 efficacy and safety studies and subsequent open-label extension studies. In these two studies combined, 554 patients received fesoterodine fumarate 4 mg/day and 566 patients received fesoterodine fumarate 8 mg/day.

    In Phase 2 and 3 placebo-controlled trials combined, the incidences of serious adverse events in patients receiving placebo, fesoterodine fumarate 4 mg, and fesoterodine fumarate 8 mg were 1.9%, 3.5%, and 2.9%, respectively. All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving fesoterodine fumarate who reported one serious adverse reaction each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.

    The most commonly reported adverse event in patients treated with fesoterodine fumarate was dry mouth. The incidence of dry mouth was higher in those taking 8 mg/day (35%) and in those taking 4 mg/day (19%), as compared to placebo (7%). Dry mouth led to discontinuation in 0.4%, 0.4%, and 0.8% of patients receiving placebo, fesoterodine fumarate 4 mg, and fesoterodine fumarate 8 mg, respectively. For those patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment.

    The second most commonly reported adverse event was constipation. The incidence of constipation was 2% in those taking placebo, 4% in those taking 4 mg/day, and 6% in those taking 8 mg/day.

    Table 4 lists adverse events, regardless of causality, that were reported in the combined Phase 3, randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with fesoterodine fumarate 4 mg or 8 mg once daily for up to 12-weeks.



    Table 4: Adverse Events with an Incidence Exceeding the Placebo Rate and Reported by ≥1% of Patients from Double-Blind, Placebo-Controlled Phase 3 Trials of 12-weeks Treatment Duration
     






    System organ class/Preferred term 


    Placebo

    N=554
    % 


    Fesoterodine fumarate

    4 mg/day

    N=554
    % 


    Fesoterodine fumarate

    8 mg/day

    N=566
    % 
    Gastrointestinal disorders
    		 
    		 
    		 
         Dry mouth
    		7
    		18.8
    		34.6
         Constipation
    		2
    		4.2
    		6
         Dyspepsia
    		0.5
    		1.6
    		2.3
         Nausea
    		1.3
    		0.7
    		1.9
         Abdominal pain upper
    		0.5
    		1.1
    		0.5
    Infections
    		 
    		 
    		 
         Urinary tract infection
    		3.1
    		3.2
    		4.2
         Upper respiratory tract infection
    		2.2
    		2.5
    		1.8
    Eye disorders
    		 
    		 
    		 
         Dry eyes
    		0
    		1.4
    		3.7
    Renal and urinary disorders
    		 
    		 
    		 
         Dysuria
    		0.7
    		1.3
    		1.6
         Urinary retention
    		0.2
    		1.1
    		1.4
    Respiratory disorders
    		 
    		 
    		 
         Cough
    		0.5
    		1.6
    		0.9
         Dry throat
    		0.4
    		0.9
    		2.3
    General disorders
    		 
    		 
    		 
         Edema peripheral
    		0.7
    		0.7
    		1.2
    Musculoskeletal disorders
    		 
    		 
    		 
         Back pain
    		0.4
    		2
    		0.9
    Psychiatric disorders
    		 
    		 
    		 
         Insomnia
    		0.5
    		1.3
    		0.4
    Investigations
    		 
    		 
    		 
         ALT increased
    		0.9
    		0.5
    		1.2
         GGT increased
    		0.4
    		0.4
    		1.2
    Skin disorders
    		 
    		 
    		 
         Rash
    		0.5
    		0.7
    		1.1


    ALT = alanine aminotransferase; GGT = gamma glutamyltransferase

    Patients also received fesoterodine fumarate for up to three years in open-label extension phases of one Phase 2 and two Phase 3 controlled trials. In all open-label trials combined, 857, 701, 529, and 105 patients received fesoterodine fumarate for at least 6 months, 1 year, 2 years, and 3 years, respectively. The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain. Similar to the controlled studies, most adverse events of dry mouth and constipation were mild to moderate in intensity. Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).


    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

    6.2 Post-marketing Experience

    The following adverse reactions have been identified during post-approval use of fesoterodine fumarate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
    Cardiac disorders: Palpitations
    Central nervous system disorders: Dizziness, headache, somnolence
    Eye disorders: Blurred vision
    General disorders and administrative site conditions: Hypersensitivity reactions, including angioedema with airway obstruction, face edema
    Skin and subcutaneous tissue disorders: Urticaria, pruritus


  • 7 DRUG INTERACTIONS

    7.1 Antimuscarinic Drugs

    Coadministration of fesoterodine fumarate with other antimuscarinic agents that produce dry mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.

    7.2 CYP3A4 Inhibitors

    Doses of fesoterodine fumarate greater than 4 mg are not recommended in adult patients taking strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin [see Dosage and Administration (2.5)].


    In a study in adults, coadministration of the strong CYP3A4 inhibitor ketoconazole with fesoterodine led to approximately a doubling of the maximum concentration (Cmax) and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine. Compared with CYP2D6 extensive metabolizers not taking ketoconazole, further increases in the exposure to 5-HMT were observed in subjects who were CYP2D6 poor metabolizers taking ketoconazole [see Clinical Pharmacology (12.3)].


    There is no clinically relevant effect of moderate CYP3A4 inhibitors on the pharmacokinetics of fesoterodine. Following blockade of CYP3A4 by coadministration of the moderate CYP3A4 inhibitor fluconazole 200 mg twice a day for 2 days, the average (90% confidence interval) increase in Cmax and AUC of the active metabolite of fesoterodine was approximately 19% (11% to 28%) and 27% (18% to 36%) respectively. No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, diltiazem, verapamil and grapefruit juice). 

    The effect of weak CYP3A4 inhibitors (e.g. cimetidine) was not examined; it is not expected to be in excess of the effect of moderate inhibitors [see Clinical Pharmacology (12.3)].


    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

    7.3 CYP3A4 Inducers

    No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. Following induction of CYP3A4 by coadministration of rifampin 600 mg once a day, Cmax and AUC of the active metabolite of fesoterodine decreased by approximately 70% and 75%, respectively, after oral administration of fesoterodine fumarate 8 mg. The terminal half-life of the active metabolite was not changed.

    7.4 CYP2D6 Inhibitors

    The interaction with CYP2D6 inhibitors was not tested clinically. In poor metabolizers for CYP2D6, representing a maximum CYP2D6 inhibition, Cmax and AUC of the active metabolite are increased 1.7- and 2-fold, respectively.

    No dosing adjustments are recommended in the presence of CYP2D6 inhibitors.

    7.5 Drugs Metabolized by Cytochrome P450

    In vitro data indicate that at therapeutic concentrations, the active metabolite of fesoterodine does not have the potential to inhibit or induce Cytochrome P450 enzyme systems [see Clinical Pharmacology (12.3)].

    7.6 Oral Contraceptives

    In the presence of fesoterodine, there are no clinically significant changes in the plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgestrel [see Clinical Pharmacology (12.3)].

    7.7 Warfarin

    A clinical study has shown that fesoterodine 8 mg once daily has no significant effect on the pharmacokinetics or the anticoagulant activity (PT/INR) of warfarin 25 mg. Standard therapeutic monitoring for warfarin should be continued [see Clinical Pharmacology (12.3)].

    7.8 Drug-Laboratory Test Interactions

    Interactions between fesoterodine fumarate and laboratory tests have not been studied.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no available data with the use of fesoterodine in pregnant women and adolescents to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of fesoterodine to pregnant mice and rabbits during organogenesis resulted in fetotoxicity at maternal exposures that were 6 and 3 times respectively the maximum recommended human dose (MRHD) of 8 mg/day, based on AUC (see Data). The background risk of major birth defects and miscarriage for the indicated population are unknown. However, in the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.


    Data


    Animal Data

     No dose-related teratogenicity was observed in reproduction studies performed in mice and rabbits. In mice at 6 to 27 times the expected exposure at the maximum recommended human dose (MRHD) of 8 mg based on AUC (75 mg/kg/day, oral), increased resorptions and decreased live fetuses were observed. One fetus with cleft palate was observed at each dose (15, 45, and 75 mg/kg/day), at an incidence within the background historical range. In rabbits treated at 3 to 11 times the MRHD (27 mg/kg/day, oral), incompletely ossified sternebrae (retardation of bone development) and reduced survival were observed in fetuses. In rabbits at 9 to 11 times the MRHD (4.5 mg/kg/day, subcutaneous), maternal toxicity and incompletely ossified sternebrae were observed in fetuses (at an incidence within the background historical range). In rabbits at 3 times the MRHD (1.5 mg/kg/day, subcutaneous), decreased maternal food consumption in the absence of any fetal effects was observed. Oral administration of 30 mg/kg/day fesoterodine to mice in a pre- and post-natal development study resulted in decreased body weight of the dams and delayed ear opening of the pups. No effects were noted on mating and reproduction of the F1 dams or on the F2 offspring.

    8.2 Lactation

    Risk Summary
    There is no information on the presence of fesoterodine in human milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for fesoterodine fumarate and any potential adverse effects on the breastfed child from fesoterodine fumarate or from the underlying maternal condition.


    8.4 Pediatric Use

    The safety and effectiveness of fesoterodine fumarate have not been established in pediatric patients younger than 6 years of age or weighing 25 kg or less.


    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.


    8.5 Geriatric Use

    No dose adjustment is recommended for the elderly. The pharmacokinetics of fesoterodine are not significantly influenced by age.


     Of the 1,567 patients who received fesoterodine fumarate 4 mg or 8 mg orally once daily in Phase 2 and 3, placebo-controlled, efficacy and safety studies for OAB, 515 (33%) were 65 years of age or older, and 140 (9%) were 75 years of age or older. No overall differences in effectiveness was observed between patients younger than 65 years of age and those 65 years of age or older in these studies. However, the incidence of antimuscarinic adverse reactions, including dry mouth, constipation, dyspepsia, increase in residual urine, dizziness (8 mg only) and urinary tract infection, was higher in patients 75 years of age and older as compared to younger patients [see Clinical Studies (14.1) and Adverse Reactions (6)].


    8.6 Renal Impairment

    In adult patients with severe renal impairment (CLCR <30 mL/min), Cmax and AUC are increased 2- and 2.3-fold, respectively. Doses of fesoterodine fumarate greater than 4 mg are not recommended in adult patients with severe renal impairment. In patients with mild or moderate renal impairment (CLCR ranging from 30 to 80 mL/min), Cmax and AUC of the active metabolite are increased up to 1.5- and 1.8-fold, respectively, as compared to healthy subjects. No dose adjustment is recommended in patients with mild or moderate renal impairment [see Clinical Pharmacology (12.3) and Dosage and Administration (2.3)].

      

    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

    8.7 Hepatic Impairment

    Patients with severe hepatic impairment (Child-Pugh C) have not been studied; therefore, fesoterodine fumarate is not recommended for use in these patients. In patients with moderate (Child-Pugh B) hepatic impairment, Cmax and AUC of the active metabolite are increased 1.4- and 2.1-fold, respectively, as compared to healthy subjects. No dose adjustment is recommended in patients with mild or moderate hepatic impairment [see Clinical Pharmacology (12.3)].


  • 10 OVERDOSAGE

    Overdosage with fesoterodine fumarate can result in severe anticholinergic effects. Treatment should be symptomatic and supportive. In the event of overdosage, ECG monitoring is recommended.

  • 11 DESCRIPTION

    Fesoterodine fumarate tablet contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is rapidly de-esterified to its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl tolterodine, which is a muscarinic receptor antagonist.
    Chemically, fesoterodine fumarate is designated as isobutyric acid 2-((R)-3-diisopropylammonium-1-phenylpropyl)-4-(hydroxymethyl) phenyl ester hydrogen fumarate. The empirical formula is C30H41NO7 and its molecular weight is 527.66. The structural formula is:
    Structure

    The asterisk (*) indicates the chiral carbon.
    Fesoterodine fumarate is a white to off-white powder, it is soluble in water, freely soluble in methanol and practically insoluble in heptane. Each fesoterodine fumarate extended-release tablet contains either 4 mg or 8 mg of fesoterodine fumarate and the following inactive ingredients: pullulan, microcrystalline cellulose, lactose monohydrate, hypromellose, hydroxypropyl cellulose, talc, glyceryl behenate, polyvinyl alcohol, polyethylene glycol, FD&C blue No. 2 aluminum lake, titanium dioxide and soya lecithin. 

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Fesoterodine is a competitive muscarinic receptor antagonist. After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine.

    Muscarinic receptors play a role in contractions of urinary bladder smooth muscle. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine produces its effects.


    12.2 Pharmacodynamics

    In a urodynamic study involving patients with involuntary detrusor contractions, the effects after the administration of fesoterodine on the volume at first detrusor contraction and bladder capacity were assessed. Administration of fesoterodine increased the volume at first detrusor contraction and bladder capacity in a dose-dependent manner. These findings are consistent with an antimuscarinic effect on the bladder.

    Cardiac Electrophysiology: The effect of fesoterodine 4 mg and 28 mg on the QT interval was evaluated in a double-blind, randomized, placebo- and positive-controlled (moxifloxacin 400 mg once a day) parallel trial with once-daily treatment over a period of 3 days in 261 male and female subjects aged 44 to 65 years. Electrocardiographic parameters were measured over a 24-hour period at pre-dose, after the first administration, and after the third administration of study medication. Fesoterodine 28 mg was chosen because this dose, when administered to CYP2D6 extensive metabolizers, results in an exposure to the active metabolite that is similar to the exposure in a CYP2D6 poor metabolizer receiving fesoterodine 8 mg together with CYP3A4 blockade. Corrected QT intervals (QTc) were calculated using Fridericia’s correction and a linear individual correction method. Analyses of 24-hour average QTc, time-matched baseline-corrected QTc, and time-matched placebo-subtracted QTc intervals indicate that fesoterodine at doses of 4 and 28 mg/day did not prolong the QT interval. The sensitivity of the study was confirmed by positive QTc prolongation by moxifloxacin.

    In this study, conducted in subjects aged 44 to 65 years, fesoterodine fumarate was associated with an increase in heart rate that correlates with increasing dose. When compared to placebo, the mean increase in heart rate associated with fesoterodine 4 mg/day and fesoterodine
    28 mg/day was 3 beats/minute and 11 beats/minute, respectively.

    In the two, phase 3, placebo-controlled studies in adult in patients with overactive bladder, the mean increases in heart rate compared to placebo were approximately 3 to 4 beats/minute in the fesoterodine 4 mg/day group and 3 to 5 beats/minute in the fesoterodine 8 mg/day group.

    12.3 Pharmacokinetics


    Absorption: After oral administration, fesoterodine is well absorbed. Due to rapid and extensive hydrolysis by nonspecific esterases to its active metabolite 5-hydroxymethyl tolterodine, fesoterodine cannot be detected in plasma. Bioavailability of the active metabolite is 52%. After single or multiple-dose oral administration of fesoterodine in doses from 4 mg to 28 mg, plasma concentrations of the active metabolite are proportional to the dose. Maximum plasma levels are reached after approximately 5 hours. No accumulation occurs after multiple-dose administration.

    A summary of pharmacokinetic parameters for the active metabolite after a single dose of fesoterodine fumarate 4 mg and 8 mg in extensive and poor metabolizers of CYP2D6 is provided in Table 8.


    Table 8: Summary of geometric mean [CV] pharmacokinetic parameters for the active metabolite after a single dose of fesoterodine fumarate 4 mg and 8 mg in extensive and poor CYP2D6 metabolizers


     
    		Fesoterodine fumarate 4 mg 
    		Fesoterodine fumarate 8 mg 
    Parameter
    		EM (N=16)
    		PM (N=8)
    		EM (N=16)
    		PM (N=8)
    Cmax (ng/mL) 
    		1.89 [43%] 
    		3.45 [54%] 
    		3.98 [28%] 
    		6.9 [39%] 
    AUC0-tz (ng*h/mL) 
    		21.2 [38%] 
    		40.5 [31%] 
    		45.3 [32%] 
    		88.7 [36%] 
    tmax (h)a 
    		5 [2 to 6] 
    		5 [5 to 6] 
    		5 [3 to 6] 
    		5 [5 to 6] 
    t½ (h) 
    		7.31 [27%] 
    		7.31 [30%] 
    		8.59 [41%] 
    		7.66 [21%] 

    EM = extensive CYP2D6 metabolizer, PM = poor CYP2D6 metabolizer, CV = coefficient of variation; Cmax = maximum plasma concentration, AUC0-tz = area under the concentration time curve from zero up to the last measurable plasma concentration, tmax = time to reach Cmax, t½ = terminal half-life
    a Data presented as median (range)

    Effect of Food:     There is no clinically relevant effect of food on the pharmacokinetics of fesoterodine. In a study of the effects of food on the pharmacokinetics of fesoterodine in 16 healthy male volunteers, concomitant food intake increased the active metabolite of fesoterodine AUC by approximately 19% and Cmax by 18% [see Dosage and Administration (2.1)].
    Distribution:     Plasma protein binding of the active metabolite is low (approximately 50%) and is primarily bound to albumin and alpha-1-acid glycoprotein. The mean steady-state volume of distribution following intravenous infusion of the active metabolite is 169 L.

    Metabolism:     After oral administration, fesoterodine is rapidly and extensively hydrolyzed to its active metabolite. The active metabolite is further metabolized in the liver to its carboxy, carboxy-N-desisopropyl, and N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A4. None of these metabolites contribute significantly to the antimuscarinic activity of fesoterodine.

    Variability in CYP2D6 Metabolism:     A subset of individuals (approximately 7% of Caucasians and approximately 2% of African Americans) are poor metabolizers for CYP2D6. Cmax and AUC of the active metabolite are increased 1.7- and 2-fold, respectively, in CYP2D6 poor metabolizers, as compared to extensive metabolizers.

    Excretion:     Hepatic metabolism and renal excretion contribute significantly to the elimination of the active metabolite. After oral administration of fesoterodine, approximately 70% of the administered dose was recovered in urine as the active metabolite (16%), carboxy metabolite (34%), carboxy-N-desisopropyl metabolite (18%), or N-desisopropyl metabolite (1%), and a smaller amount (7%) was recovered in feces.

    The terminal half-life of the active metabolite is approximately 4 hours following an intravenous administration. The apparent terminal half-life following oral administration is approximately 7 hours.

       Pharmacokinetics in Specific Populations

     

    Geriatric Patients: Following a single 8 mg oral dose of fesoterodine, the mean (±SD) AUC and Cmax for the active metabolite 5-hydroxymethyl tolterodine in 12 elderly men (mean age 67 years) were 51.8 ± 26.1 h*ng/mL and 3.8 ± 1.7 ng/mL, respectively. In the same study, the mean (±SD) AUC and Cmax in 12 young men (mean age 30 years) were 52 ± 31.5 h*ng/mL and 4.1 ± 2.1 ng/mL, respectively. The pharmacokinetics of fesoterodine were not significantly influenced by age [see Use in Specific Populations (8.5)]. 
    Gender:     Following a single 8 mg oral dose of fesoterodine, the mean (±SD) AUC and Cmax for the active metabolite 5-hydroxymethyl tolterodine in 12 elderly men (mean age 67 years) were 51.8 ± 26.1 h*ng/mL and 3.8 ± 1.7 ng/mL, respectively. In the same study, the mean (±SD) AUC and Cmax in 12 elderly women (mean age 68 years) were 56 ± 28.8 h*ng/mL and 4.6 ± 2.3 ng/mL, respectively. The pharmacokinetics of fesoterodine were not significantly influenced by gender.

    Race:     The effects of Caucasian or Black race on the pharmacokinetics of fesoterodine were examined in a study of 12 Caucasian and 12 Black African young male volunteers. Each subject received a single oral dose of 8 mg fesoterodine. The mean (±SD) AUC and Cmax for the active metabolite 5-hydroxymethyl tolterodine in Caucasian males were 73 ± 27.8 h*ng/mL and 6.1 ± 2.7 ng/mL, respectively. The mean (±SD) AUC and Cmax in Black males were 65.8 ± 23.2 h*ng/mL and 5.5 ± 1.9 ng/mL, respectively. The pharmacokinetics of fesoterodine were not significantly influenced by race.

    Renal Impairment:     In patients with mild or moderate renal impairment (CLCR ranging from 30 to 80 mL/min), Cmax and AUC of the active metabolite are increased up to 1.5- and 1.8-fold, respectively, as compared to healthy subjects. In patients with severe renal impairment (CLCR <30 mL/min), Cmax and AUC are increased 2- and 2.3-fold, respectively [see Use in Specific Populations (8.6), Warnings and Precautions (5.7), and Dosage and Administration (2.3)].

    Hepatic Impairment:     In patients with moderate (Child-Pugh B) hepatic impairment, Cmax and AUC of the active metabolite are increased 1.4- and 2.1-fold, respectively, as compared to healthy subjects.

    Subjects with severe hepatic impairment (Child-Pugh C) have not been studied [see Use in Specific Populations (8.7)].
     Drug-Drug Interactions 
    Drugs Metabolized by Cytochrome P450:     At therapeutic concentrations, the active metabolite of fesoterodine does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4, or induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 in vitro [see Drug Interactions (7.5)].

    CYP3A4 Inhibitors:     Following blockade of CYP3A4 by coadministration of the strong CYP3A4 inhibitor ketoconazole 200 mg twice a day for 5 days, Cmax and AUC of the active metabolite of fesoterodine increased 2- and 2.3-fold, respectively, after oral administration of fesoterodine fumarate 8 mg to CYP2D6 extensive metabolizers. In CYP2D6 poor metabolizers, Cmax and AUC of the active metabolite of fesoterodine increased 2.1- and 2.5-fold, respectively, during coadministration of ketoconazole 200 mg twice a day for 5 days. Cmax and AUC were 4.5- and 5.7-fold higher, respectively, in subjects who were CYP2D6 poor metabolizers and taking ketoconazole compared to subjects who were CYP2D6 extensive metabolizers and not taking ketoconazole. In a separate study coadministering fesoterodine with ketoconazole 200 mg once a day for 5 days, the Cmax and AUC values of the active metabolite of fesoterodine were increased 2.2-fold in CYP2D6 extensive metabolizers and 1.5- and 1.9-fold, respectively, in CYP2D6 poor metabolizers. Cmax and AUC were 3.4- and 4.2-fold higher, respectively, in subjects who were CYP2D6 poor metabolizers and taking ketoconazole compared to subjects who were CYP2D6 extensive metabolizers and not taking ketoconazole.

    There is no clinically relevant effect of moderate CYP3A4 inhibitors on the pharmacokinetics of fesoterodine. In a drug-drug interaction study evaluating the coadministration of the moderate CYP3A4 inhibitor fluconazole 200 mg twice a day for 2 days, a single 8 mg dose of fesoterodine was administered 1 hour following the first dose of fluconazole on day 1 of the study. The average (90% confidence interval) for the increase in Cmax and AUC of the active metabolite of fesoterodine was approximately 19% (11% to 28%) and 27% (18% to 36%) respectively.

    The effect of weak CYP3A4 inhibitors (e.g. cimetidine) was not examined; it is not expected to be in excess of the effect of moderate inhibitors [see Drug Interactions (7.2), Warnings and Precautions (5.8), and Dosage and Administration (2.3)].

    CYP3A4 Inducers:     Following induction of CYP3A4 by coadministration of rifampicin 600 mg once a day, Cmax and AUC of the active metabolite of fesoterodine decreased by approximately 70% and 75%, respectively, after oral administration of fesoterodine fumarate 8 mg. The terminal half-life of the active metabolite was not changed.

    Induction of CYP3A4 may lead to reduced plasma levels. No dosing adjustments are recommended in the presence of CYP3A4 inducers [see Drug Interactions (7.3)].

    CYP2D6 Inhibitors:     The interaction with CYP2D6 inhibitors was not studied. In poor metabolizers for CYP2D6, representing a maximum CYP2D6 inhibition, Cmax and AUC of the active metabolite are increased 1.7- and 2-fold, respectively [see Drug Interactions (7.4)].

    Oral Contraceptives    : Thirty healthy female subjects taking an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel were evaluated in a 2-period cross-over study. Each subject was randomized to receive concomitant administration of either placebo or fesoterodine 8 mg once daily on days 1 to 14 of hormone cycle for 2 consecutive cycles. Pharmacokinetics of ethinyl estradiol and levonorgestrel were assessed on day 13 of each cycle. Fesoterodine increased the AUC and Cmax of ethinyl estradiol by 1 to 3% and decreased the AUC and Cmax of levonorgestrel by 11 to 13% [see Drug Interactions (7.6)].

    Warfarin:     In a cross-over study in 14 healthy male volunteers (18 to 55 years), a single oral dose of warfarin 25 mg was given either alone or on day 3 of once daily dosing for 9 days with fesoterodine 8 mg. Compared to warfarin alone dosing, the Cmax and AUC of S-warfarin were lower by ~ 4%, while the Cmax and AUC of R-warfarin were lower by approximately 8% and 6% for the coadministration, suggesting absence of a significant pharmacokinetic interaction.

    There were no statistically significant changes in the measured pharmacodynamic parameters for anticoagulant activity of warfarin (INRmax, AUCINR), with only a small decrease noted in INRmax of ~ 3% with the co-administration relative to warfarin alone. INR versus time profiles across individual subjects in the study suggested some differences following co-administration with fesoterodine, although there was no definite trend with regard to the changes noted [see Drug Interactions (7.7)].


    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis,Mutagenesis,Impairment of Fertility

    Carcinogenicity
    No evidence of drug-related carcinogenicity was found in 24-month studies with oral administration to mice and rats. The highest tolerated doses in mice (females 45 to 60 mg/kg/day, males 30 to 45 mg/kg/day) correspond to 11 to 19 times (females) and 4 to 9 times (males) the estimated human AUC values reached with fesoterodine 8 mg, which is the Maximum Recommended Human Dose (MRHD). In rats, the highest tolerated dose (45 to 60 mg/kg/day) corresponds to 3 to 8 times (females) and 3 to 14 times (males) the estimated human AUC at the MRHD.

    Mutagenesis
    Fesoterodine was not mutagenic or genotoxic in vitro (Ames tests, chromosome aberration tests) or in vivo (mouse micronucleus test).

    Impairment of Fertility
    Fesoterodine had no effect on male reproductive function or fertility at doses up to 45 mg/kg/day in mice. At 45 mg/kg/day, a lower number of corpora lutea, implantation sites and viable fetuses was observed in female mice administered fesoterodine for 2-weeks prior to mating and continuing through day 7 of gestation. The maternal No-Observed-Effect Level (NOEL) and the NOEL for effects on reproduction and early embryonic development were both 15 mg/kg/day. At the NOEL, the systemic exposure, based on AUC, was 0.6 to 1.5 times higher in mice than in humans at the MRHD, whereas based on peak plasma concentrations, the exposure in mice was 5 to 9 times higher.


  • 14 CLINICAL STUDIES

    14.1 Adult Overactive Bladder

    The efficacy of fesoterodine fumarate extended-release tablets was evaluated in two, Phase 3, randomized, double-blind, placebo-controlled, 12-week studies for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Entry criteria required that patients have symptoms of overactive bladder for ≥6-months duration, at least 8 micturitions per day, and at least 6 urinary urgency episodes or 3 urge incontinence episodes per 3-day diary period. Patients were randomized to a fixed dose of fesoterodine fumarate 4 or 8 mg/day or placebo. In one of these studies, 290 patients were randomized to an active control arm (an oral antimuscarinic agent). For the combined studies, a total of 554 patients received placebo, 554 patients received fesoterodine fumarate 4 mg/day, and 566 patients received fesoterodine fumarate 8 mg/day. The majority of patients were Caucasian (91%) and female (79%) with a mean age of 58 years (range 19 to 91 years).
    The primary efficacy endpoints were the mean change in the number of urge urinary incontinence episodes per 24 hours and the mean change in the number of micturitions (frequency) per 24 hours. An important secondary endpoint was the mean change in the voided volume per micturition.
    Results for the primary endpoints and for mean change in voided volume per micturition from the two 12-week clinical studies of fesoterodine fumarate are reported in Table 10.
    Table 10: Mean baseline and change from baseline to Week 12 for urge urinary incontinence episodes, number of micturitions, and volume voided per micturition

      
         		 Study 1
         		 Study 2
     
     Parameter
         		 Placebo N=279
         		 Fesoterodine fumarate 4mg/day N=265
         		 Fesoterodine fumarate 8mg/day N=276
         		 Placebo N=266
         		 Fesoterodine fumarate 4mg/day N=267
         		 Fesoterodine fumarate 8mg/day N=267
     
     Number of urge incontinence episodes per 24 hoursa
     
     Baseline
         		 3.7
         		 3.8
         		 3.7
         		 3.7
         		 3.9
         		 3.9
     
     Change of baseline
         		 -1.20
         		 -2.06
         		 -2.27
         		 -1
         		 -1.77
         		 -2.42
     
     p-value vs. placebo
         		 -
         		 0.001
         		 <0.001
         		 -
         		 <0.003
         		 <0.001
     
     Number of micturitions per 24 hours
     
     Baseline
         		 12
         		 11.6
         		 11.9
         		 12.2
         		 12.9
         		 12
     
     Change of baseline
         		 -1.02
         		 -1.74
         		 -1.94
         		 -1.02
         		 -1.86
         		 -1.94
     
     p-value vs. placebo
         		 -
         		 <0.001
         		 <0.001
         		 -
         		 0.032
         		 <0.001
     
     Voided volume per micturition (mL)
     
     Baseline
         		 150
         		 160
         		 154
         		 159
         		 152
         		 156
     
     Change of baseline
         		 10
         		 27
         		 33
         		 8
         		 17
         		 33
     
     p-value vs. placebo
         		 -
         		 <0.001
         		 <0.001
         		 -
         		 0.150
         		 <0.001
     

    vs. = versus
    a Only those patients who were urge incontinent at baseline were included for the analysis of number of urge incontinence episodes per 24 hours: In Study 1, the number of these patients was 211, 199, and 223 in the placebo, fesoterodine fumarate 4 mg/day and fesoterodine fumarate 8 mg/day groups, respectively. In Study 2, the number of these patients was 205, 228, and 218, respectively.
    Figures 1 to 4: The following figures show change from baseline over time in number of micturitions and urge urinary incontinence episodes per 24 h in the two studies.

    fesoterodine-figure1.jpg

    fesoterodine-figure2.jpg


    fesoterodine-figure3.jpg

    fesoterodine-figure4.jpg


    A reduction in number of urge urinary incontinence episodes per 24 hours was observed for both doses as compared to placebo as early as two weeks after starting fesoterodine fumarate therapy.

    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.


  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Fesoterodine fumarate extended-release tablets 4 mg are dark blue, oval, biconvex, film-coated tablets debossed with L376 on one side and plain on other side. They are supplied as follows:
    NDC: 62332-175-30 bottle of 30 tablets with child resistant closure
    NDC: 62332-175-90 bottle of 90 tablets with child resistant closure
    NDC: 62332-175-91 bottle of 1000 tablets
    NDC: 62332-175-10 carton of 100 (l0 x 10) unit dose tablets

    Fesoterodine fumarate extended-release tablets 8 mg are light blue, oval, biconvex, film-coated tablets debossed with L377 on one side and plain on other side. They are supplied as follows:
    NDC: 62332-176-30 bottle of 30 tablets with child resistant closure
    NDC: 62332-176-90 bottle of 90 tablets with child resistant closure
    NDC: 62332-176-91 bottle of 1000 tablets
    NDC: 62332-176-10 carton of 100 (l0 x 10) unit dose tablets

    Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).

    Angioedema
    Inform patients and/or their caregivers that fesoterodine fumarate may cause angioedema, which could result in life-threatening airway obstruction. Advise patients and/or their caregivers to promptly discontinue fesoterodine fumarate and seek immediate medical attention if they experience edema of the lips, tongue or laryngopharynx, or difficulty breathing.

    Antimuscarinic Effects
    Inform patients that fesoterodine fumarate, like other antimuscarinic agents, may produce clinically significant adverse effects related to antimuscarinic pharmacological activity including constipation and urinary retention. Fesoterodine fumarate, like other antimuscarinics, may be associated with blurred vision, therefore, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug’s effects on the patient have been determined. Heat prostration (due to decreased sweating) can occur when fesoterodine fumarate, like other antimuscarinic drugs, is used in a hot environment.

    Alcohol
    Patients should also be informed that alcohol may enhance the drowsiness caused by fesoterodine fumarate, like other anticholinergic agents.

  • Patient Information

    Fesoterodine (FES-oh-TER-oh-deen) Fumarate

    Extended-release Tablets, for oral use 


    Read the Patient Information that comes with fesoterodine fumarate extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.

    What are fesoterodine fumarate extended-release tablets?

    Fesoterodine fumarate extended-release tablets are a prescription medicine used:
    in adults to treat symptoms of a condition called overactive bladder (OAB), including urge urinary incontinence (leaking or wetting accidents due to a strong need to urinate), urinary urgency (having a strong need to urinate right away), or urinary frequency (having to urinate too often).

    It is not known if fesoterodine fumarate extended-release tablets are safe and effective in children younger than 6 years of age or with a body weight 55 pounds (25 kg) or less.

    Who should not take fesoterodine fumarate extended-release tablets? 

    Do not take fesoterodine fumarate extended-release tablets if you:

      are allergic to fesoterodine fumarate extended-release tablets or any of its ingredients. See the end of this leaflet for a complete list of ingredients.
      are allergic to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules.
      are not able to empty your bladder (urinary retention).
      have delayed or slow emptying of your stomach (gastric retention).
      have an eye problem called uncontrolled narrow-angle glaucoma.


    Before you take fesoterodine fumarate extended-release tablets, tell your healthcare provider about all your medical conditions, including if you:
      have problems emptying your bladder or you have a weak urine stream.
      have any stomach or intestinal problems, or problems with constipation.
      are receiving treatment for an eye problem called narrow-angle glaucoma.
      have a condition called Myasthenia Gravis.
      have kidney problems.
      have liver problems.
      are pregnant or plan to become pregnant. It is not known if fesoterodine fumarate extended-release tablets will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.

      are breastfeeding or plan to breastfeed. It is not known if fesoterodine fumarate passes into your breast milk. You should talk to your healthcare provider about the best way to feed your baby while taking fesoterodine fumarate extended-release tablets.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal products. Fesoterodine fumarate extended-release tablets may affect the way other medicines work, and other medicines may affect how fesoterodine fumarate extended-release tablets works. Especially tell your healthcare provider if you are taking antimuscarinic, antibiotics, or antifungal medicines.
    Know all the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist each time you get a new medicine.


    How should I take fesoterodine fumarate extended-release tablets? 

      Take fesoterodine fumarate extended-release tablets exactly as your healthcare provider tells you to take it.
      Your healthcare provider may lower your dose of fesoterodine fumarate extended-release tablets if you are an adult with severe kidney problems.
      Take fesoterodine fumarate extended-release tablets with liquid and swallow the tablet whole. Do not chew, divide, or crush the tablet.
      Take fesoterodine fumarate extended-release tablets with or without food.
      If you miss a dose of fesoterodine fumarate extended-release tablets, begin taking fesoterodine fumarate extended-release tablets again the next day. Do not take 2 doses of fesoterodine fumarate extended-release tablets in the same day.
      If you take too much fesoterodine fumarate extended-release tablets, call your healthcare provider or go to an emergency department right away.

    What should I avoid while taking fesoterodine fumarate extended-release tablets?
      Fesoterodine fumarate extended-release tablets can cause blurred vision, dizziness, and drowsiness. Do not drive, operate machinery, or do other dangerous activities until you know how fesoterodine fumarate extended-release tablets affects you.
      Use caution in hot environments. Decreased sweating and severe heat illness can happen when medicines such as fesoterodine fumarate extended-release tablets are used in a hot environment.
      Drinking alcohol while taking medicines such as fesoterodine fumarate extended-release tablets may cause increased drowsiness.

    What are the possible side effects of fesoterodine fumarate extended-release tablets?

    Fesoterodine fumarate extended-release tablets may cause serious side effects, including:
      serious allergic reactions. Symptoms of a serious allergic reaction may include swelling of the face, lips, throat, or tongue. If you have any of these symptoms, you should stop taking fesoterodine fumarate extended-release tablets and get emergency medical help right away.
      inability to empty bladder (urinary retention). Fesoterodine fumarate extended-release tablets may increase your chances of not being able to empty your bladder if you have bladder outlet obstruction. Tell your healthcare provider right away if you are unable to empty your bladder.
      central nervous system (CNS) effects. Talk to your healthcare provider right away if you get any of these side effects: headache, dizziness, and drowsiness.
      worsening of Myasthenia Gravis symptoms.

    The most common side effects of fesoterodine fumarate extended-release tablets in adults include:

    dry mouth
    constipation

    Talk to your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of fesoterodine fumarate extended-release tablets. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store fesoterodine fumarate extended-release tablets?

      Store fesoterodine fumarate extended-release tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F).
      Protect the medicine from moisture by keeping the bottle closed tightly.
      Keep fesoterodine fumarate extended-release tablets and all medicines out of the reach of children.

    General information about the safe and effective use of fesoterodine fumarate extended-release tablets 

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use fesoterodine fumarate extended-release tablets for a condition for which it was not prescribed. Do not give fesoterodine fumarate extended-release tablets to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about fesoterodine fumarate extended-release tablets that is written for health professionals.  

    What are the ingredients in fesoterodine fumarate extended-release tablets? 

    Active ingredient: fesoterodine fumarate

    Inactive ingredients: pullulan, microcrystalline cellulose, lactose monohydrate, hypromellose, hydroxypropyl cellulose, talc, glyceryl behenate, polyvinyl alcohol, polyethylene glycol, FD&C blue No. 2 aluminum lake, titanium dioxide and soya lecithin.

    Pediatric use information is approved for Pfizer Inc.’s TOVIAZ® (fesoterodine fumarate) extended-release tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

    Trademarks are the property of their respective owners.
    This Patient Information has been approved by the U.S. Food and Drug Administration.
    For more information call Alembic Pharmaceuticals Limited at 1-866-210-9797.

    Manufactured by:
    Alembic Pharmaceuticals Limited
    (Formulation Division),
    Panelav 389350, Gujarat, India

    Manufactured for:
    Alembic Pharmaceuticals, Inc.
    Bedminster, NJ 07921, USA

    Revised: 12/2021

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -4 mg

    NDC: 62332-175-30

    Fesoterodine Fumarate

    Extended-release Tablets

    4 mg

    Rx only

    30 Tablets

    Alembic

    fesoterodine-4-mg.jpg

     


  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -8 mg

    NDC: 62332-176-30

    Fesoterodine Fumarate

    Extended-release Tablets

    8 mg

    Rx only

    30 Tablets

    Alembic

    fesoterodine-8-mg.jpg

  • INGREDIENTS AND APPEARANCE
    FESOTERODINE FUMARATE 
    fesoterodine fumarate tablet, extended release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-175
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    FESOTERODINE FUMARATE (UNII: EOS72165S7) (FESOTERODINE - UNII:621G617227) FESOTERODINE FUMARATE4 mg
    Inactive Ingredients
    Ingredient NameStrength
    PULLULAN (UNII: 8ZQ0AYU1TT)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)  
    TALC (UNII: 7SEV7J4R1U)  
    GLYCERYL DIBEHENATE (UNII: R8WTH25YS2)  
    POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)  
    POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    LECITHIN, SOYBEAN (UNII: 1DI56QDM62)  
    Product Characteristics
    ColorBLUE (Dark blue) Scoreno score
    ShapeOVAL (Biconvex) Size13mm
    FlavorImprint Code L376
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-175-3030 in 1 BOTTLE; Type 0: Not a Combination Product01/06/2023
    2NDC: 62332-175-9090 in 1 BOTTLE; Type 0: Not a Combination Product01/06/2023
    3NDC: 62332-175-911000 in 1 BOTTLE; Type 0: Not a Combination Product01/06/2023
    4NDC: 62332-175-10100 in 1 CARTON; Type 0: Not a Combination Product01/06/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20497301/06/2023
    FESOTERODINE FUMARATE 
    fesoterodine fumarate tablet, extended release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 62332-176
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    FESOTERODINE FUMARATE (UNII: EOS72165S7) (FESOTERODINE - UNII:621G617227) FESOTERODINE FUMARATE8 mg
    Inactive Ingredients
    Ingredient NameStrength
    PULLULAN (UNII: 8ZQ0AYU1TT)  
    MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)  
    HYDROXYPROPYL CELLULOSE (1600000 WAMW) (UNII: RFW2ET671P)  
    TALC (UNII: 7SEV7J4R1U)  
    GLYCERYL DIBEHENATE (UNII: R8WTH25YS2)  
    POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)  
    POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    LECITHIN, SOYBEAN (UNII: 1DI56QDM62)  
    Product Characteristics
    ColorBLUE (Light blue) Scoreno score
    ShapeOVAL (Biconvex) Size13mm
    FlavorImprint Code L377
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 62332-176-3030 in 1 BOTTLE; Type 0: Not a Combination Product01/06/2023
    2NDC: 62332-176-9090 in 1 BOTTLE; Type 0: Not a Combination Product01/06/2023
    3NDC: 62332-176-911000 in 1 BOTTLE; Type 0: Not a Combination Product01/06/2023
    4NDC: 62332-176-10100 in 1 CARTON; Type 0: Not a Combination Product01/06/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20497301/06/2023
    Labeler - Alembic Pharmaceuticals Inc. (079288842)
    Establishment
    NameAddressID/FEIBusiness Operations
    Alembic Pharmaceuticals Limited650574671MANUFACTURE(62332-175, 62332-176)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.